Author: Daniel Tillett

14 Dec

December 2022 Update

Daniel Tillett ASX Release, Featured, Media Release, Video

Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his prior role as a Non-Executive Director…

Read More
09 Dec

Race Submits Human Ethics Application to Commence Cardioprotection Breast Cancer Trial

Daniel Tillett ASX Release, Featured, Media Release , , ,

Read More
05 Dec

Danny Sharp appointed an Independent Non-Executive Director of Race

Daniel Tillett Featured

Read More
29 Nov

Race Oncology 2022 AGM Presentation

Daniel Tillett Featured, Media Release, Video , , ,

Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett.

Read More
23 Nov

Race Receives Positive Guidance on Zantrene via Pre-IND Meeting with US FDA

Daniel Tillett Featured , , ,

Read More
17 Nov

Race Oncology EMD AML Trial Featured on NBN News

Daniel Tillett Featured, Media Release, Video , ,

Read More
02 Nov

Race Oncology Investor Briefing – Melbourne 20th Oct 2022

Daniel Tillett Featured, Media Release, Video , , , ,

Read More
27 Oct

September 2022 Quarterly Activity Report & Appendix 4C

Daniel Tillett Featured

Read More
26 Oct

Pitt St Research interview with Race Oncology’s CEO Phil Lynch & CSO Dr Daniel Tillett

Daniel Tillett Featured, Media Release, Video , ,

Read More
17 Oct

Pitt Street Research Initiates Coverage of Race Oncology

Daniel Tillett Featured, Media Release, OPINION EDITORIAL , , , , ,

Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…

Read More